TY - JOUR
T1 - Neonatal BCG-vaccination and atopic dermatitis before 13 months of age. A randomised clinical trial
AU - Thøstesen, Lisbeth Marianne
AU - Kjaergaard, Jesper
AU - Pihl, Gitte Thybo
AU - Birk, Nina Marie
AU - Nissen, Thomas Nørrelykke
AU - Aaby, Peter
AU - Jensen, Aksel Karl Georg
AU - Olesen, Annette Wind
AU - Stensballe, Lone Graff
AU - Jeppesen, Dorthe Lisbeth
AU - Benn, Christine Stabell
AU - Kofoed, Poul-Erik
N1 - This article is protected by copyright. All rights reserved.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Studies have suggested that Bacillus Calmette-Guérin (BCG) vaccination may reduce the risk of allergic diseases, including atopic dermatitis. The Danish Calmette Study was conducted 2012-2015. Within 7 days of birth new-borns were randomised 1:1 to BCG or no BCG. Exclusion criteria were gestational age <32 weeks, birth weight <1000 g, known immunodeficiency or no Danish-speaking parent. Data were collected through telephone interviews and clinical examinations until 13 months. Clinical atopic dermatitis was diagnosed in 466/2,052 (22.7%) children in the BCG group and 495/1,952 (25.4%) children in the control group (RR=0.90 (95% confidence intervals 0.80 to 1.00)). The effect of neonatal BCG vaccination differed significantly between children with atopic predisposition (RR 0.84 (0.74 to 0.95)) and children without atopic predisposition (RR 1.09 (0.88 to 1.37)) (test of no interaction, p=0.04). Among children with atopic predisposition, the number-needed-to-treat with BCG to prevent one case of atopic dermatitis was 21 (12 to 76). This article is protected by copyright. All rights reserved.
AB - Studies have suggested that Bacillus Calmette-Guérin (BCG) vaccination may reduce the risk of allergic diseases, including atopic dermatitis. The Danish Calmette Study was conducted 2012-2015. Within 7 days of birth new-borns were randomised 1:1 to BCG or no BCG. Exclusion criteria were gestational age <32 weeks, birth weight <1000 g, known immunodeficiency or no Danish-speaking parent. Data were collected through telephone interviews and clinical examinations until 13 months. Clinical atopic dermatitis was diagnosed in 466/2,052 (22.7%) children in the BCG group and 495/1,952 (25.4%) children in the control group (RR=0.90 (95% confidence intervals 0.80 to 1.00)). The effect of neonatal BCG vaccination differed significantly between children with atopic predisposition (RR 0.84 (0.74 to 0.95)) and children without atopic predisposition (RR 1.09 (0.88 to 1.37)) (test of no interaction, p=0.04). Among children with atopic predisposition, the number-needed-to-treat with BCG to prevent one case of atopic dermatitis was 21 (12 to 76). This article is protected by copyright. All rights reserved.
KW - Journal Article
U2 - 10.1111/all.13314
DO - 10.1111/all.13314
M3 - Journal article
C2 - 28929567
SN - 0105-4538
VL - 73
SP - 498
EP - 504
JO - Allergy
JF - Allergy
IS - 2
ER -